

From: Kyle Greenwood <pharma@smiconferences.co.uk>
To: Kester, Tonykester@aging.sc.gov
Date: 9/6/2016 9:12:17 AM
Subject: Clinical Updates in Antibacterial Superdrugs by Janssen, AstraZeneca, Zoetis, Pfizer and North Texas Health Science Center

Superbugs & Superdrugs USA 2016

Conference: November 14th & 15th | Interactive Workshops: November 16th
Renaissance Woodbridge Hotel, Iselin, New Jersey

Register online - Secure attendance by Sept 30th to save \$200

Proudly sponsored by **Noigel** and **Polyphor**

DOWNLOAD A BROCHURE TO SEE THE FULL SPEAKER LINE-UP! FEATURED KEYNOTES INCLUDE:

[VIEW BROCHURE](#)

Dear Mr Tony Kester,

The threat of antimicrobial resistance (AMR) is regularly making front page news but what is the medical industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping?

Superbugs and Superdrugs USA will delve deeper into the heart of AMR and address key questions such as:

- How is **National Strategy** boosting drug discovery and investment?
- How are **AstraZeneca** looking at new pathways and tools to enable drug discovery?
- What can be learnt from **Phase I European clinical trials** on a new class of macrocycle antibiotics?
- How are **Pfizer** taking the non-antibiotic prophylactic approach to address unmet medical needs?
- How can gram-positive antibiotics be turned into **gram-negative therapeutics**?
- Can resistant gene products be targeted using **protein** "resistance neutralizers"?
- What can be done to tackle **zoonotic diseases**?
- **Combination therapy** use v disuse - What are the advantages and disadvantages of combining antimicrobial agents?
- How can **antibiotic toxicity** be decreased using novel strategies based on docking in drug design and TRIZ?
- What progress has been made with the development of clinical assets through **collaborative ventures**?

This is just a snap shot of what to look forward to this fall! Visit the [website](#) or [scroll down](#) for program highlights.

HOW TO REGISTER:

1. Secure your spot **online** and take advantage of the **\$200 earlybird saving**
2. For **sponsorship** enquiries contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk
3. For **delegate** enquiries and special pharma rates, contact Matthew Apps on +44 (0)20 7827 6093 or email mapps@smi-online.co.uk

WAIT THER'S MORE!

Don't forget to check out the **pre-conference interactive workshops** on Wednesday **November 16th 2016**. Both sessions have been carefully selected to bring you hands on training and complement the topics covered in the conference agenda.

A: The Use of Animal Models in Pre-Clinical Drug Development

08.30 – 12.30 | Hosted by William Weiss, Director, Pre-Clinical Services and Mark Pulse, Associate Director, Pre-Clinical Services, **UNT Health Science Centre**

Gain an understanding of what animal models can and cannot provide with in-depth discussion on proof of concept studies, the transition from *in-vitro* activity to *in-vivo* efficacy and interpretation of results.

B: Opportunities and Challenges in Development of New Antibacterial Therapeutics

13.30 – 17.30 | Hosted by Dr Tina Guina, Therapeutics Development Project Officer and Dr Francois Franceschi, Therapeutics Development Program Officer, **The National Institute of**

Allergy and Infectious Diseases

This workshop will gather experts from industry, academia and government to discuss various aspects of new antibacterial development including clinical and regulatory challenges. Attendees will also learn about funding opportunities provided by the US government for discovery/development of new antibacterial's

Contact us for packages to attend all 3 days!

AGENDA HIGHLIGHTS: DOWNLOAD A BROCHURE FOR A DETAILED PROGRAM

Day One - 14th November 2016		Day Two - 15th November 2016	
8.30	Registration & Coffee	8.30	Registration & Coffee
9.00	Chairman's Opening Remarks William Weiss , Director of Pre-Clinical Services, University of North Texas Health Science Center	9.00	Chairman's Opening Remarks William Weiss , Director of Pre-Clinical Services, University of North Texas Health Science Center
9.10	Global action plan on antimicrobial resistance Pilar Ramon-Pardo , Advisor on Clinical Management of Infectious Diseases and Antimicrobial Resistance, PAHO/WHO	9.10	First to know and fast to market Mahesh Kumar , Vice President, Global Biological Research and Development, Zoetis
9.50	NIAID and National Strategy for CARB Rosemarie Aurigemma , Chief, Biodefense Drug Development Section, DMID, NIAID, NIH	9.50	Novel protein-based biologics for the treatment and prevention of serious bacterial infections Anthony Simon Lynch , Senior Scientific Director, Janssen Fellow & Incubator Leader, Janssen Research & Development, LLC
10.30	Morning Coffee	10.30	Morning Coffee
11.00	BARDA's end-to-end support of antibacterial product development Christopher Houchens , Branch Chief, Antibacterials Program, BARDA	11.00	Antimicrobial combination therapy: Use and misuse William Weiss , Director of Pre-Clinical Services, University of North Texas Health Science Center
11.40	Enabling drug discovery and development to address the crisis of antimicrobial resistance John Rex , Senior Vice President and Chief Strategy Officer, Infection Business Unit, AstraZeneca	11.40	The novel strategy to fight multidrug resistance by multiple drugs synergism, based on docking in drug design and TRIZ Boris Farber , CEO, Noigel, LLC
12.20	Networking Lunch	12.20	Networking Lunch
1.30	POL7080 — Polyphor's new class of macrocycle antibiotic Daniel Obrecht , Chief Scientific Officer, Polyphor	1.30	What can be done in order to be successful? Domingo Gargallo-Viola , Co-Founder and CSO, ABAC Therapeutics
2.10	Progress towards developing vaccines for the prevention of Staphylococcus aureus infections Annaliesa Anderson , Vice President and CSO Bacterial Vaccines, Pfizer	2.10	Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broad spectrum activity against Class A, C and D enzymes Alita Miller , Head of Bioscience, Entasis Therapeutics
2.50	Innovative approaches to treating gram-negative infections Scott Coleman , Head of Nonclinical Development, Spero Therapeutics	2.50	Afternoon Tea
3.30	Afternoon Tea	3.20	Novel beta-lactamase inhibitors to calm the carbapenemase storm Olga Lomovskaya , Vice President, Biology, The Medicines Company
4.00	Microbial metagenomics-based antibiotic discovery		

4.40	David Pompliano, Co-Founder and CSO, Lodo Therapeutics Targeting mechanisms of resistance using protein resistance neutralizers David Cook, Chief Scientific Officer , Blueberry Therapeutics Ltd.	4.00	Collaborative development of novel drugs to prevent infection Ian Hayter, Projects Director, Destiny Pharma Ltd
5.20	Chairman's Closing Remarks and Close of Day One	4.40	Chairman's Closing Remarks and Close of Day Two

website

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>